Effect of zeta potential on the properties of nano-drug delivery systems - A review (Part 1)

Tropical Journal of Pharmaceutical Research

Volumn 12, Issue 2, 2013, Pages 255-264

  Honary, Soheyla ^a   Zahir, Foruhe ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug targeting; Nano drug delivery; Particle charge; Particle size; Zeta potential

Indexed keywords

DOXORUBICIN; FLUDROCORTISONE; FLUMETASONE PIVALATE; IMMUNOGLOBULIN; NANOPARTICLE; PACLITAXEL; SULPIRIDE;

ARTICLE; CONFOCAL MICROSCOPY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG RELEASE; EMULSION; FLOW CYTOMETRY; HUMAN; MULTIDRUG RESISTANCE; NANO DRUG DELIVERY SYSTEM; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; SKIN; TUMOR CELL; ZETA POTENTIAL;

EID: 84876923426     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v12i2.19     Document Type: Article

References (70)

1. Kutschera HL, Chaoa P, Deshmukha M, Rajana SS, Singha Y, Hua P, Josephb LB, Steina S, Laskinb DL, Sinkoa PJ. Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int. J. Pharm. 2010; 402: 64-71.
2. Khan MK. Nigavekar SS, Minc LD, Kariapper MS, Nair BM, Leniak WG, Balogh LP. In vivo biodistribution of dendrimers and dendrimer nanocomposites -implications for cancer imaging and therapy. Technol. Cancer Res. Treat. 2005; 4: 603-613.
3. Rabinovich-Guilatt L, Couvreur P, Lambert G, Goldstein D, Benita S,Dubernet C. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem.phys.lipid. 2004; 131:.1-13.
4. Chun MS, Cho H, Songb I. Electrokinetic behavior of membrane zeta potential during the filtration of colloidal suspensions. Desalination 2002; 148: 363-367.
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008; 7: 771-782.
6. Prokop A, Kozlov E, Carlesso J, Davidson M. Hydrogelbased colloidal polymeric system for protein and drug delivery: physical and chemical characterization permeability control and applications. Adv. Polymer res. 2002; 160: 119--173.
7. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules, A new platform for nanomedicine. Int. J. Pharm. 2009; 379: 201-209.
8. Singh R, Lillard JR. Nanoparticle-based targeted drug delivery, Experimental and Molecular Pathology. Exp.Mol. Pathol. 2009; 86: 215-223.
9. Agnihotri SA, Mallikavjund NN, Aminabhavi TM. Recent advances on chitosan-based micro and nanoparticles in drug delivery. J. control. Release 2004; 100: 5-28.
10. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008; 34: 592- 602.
11. Shan X, Liu C, Yuan Y, Xu F, Tao X, Sheng Y, Zhou H. In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly (ethylene-glycol)-modified PLA (BAB type) triblock copolymer. Colloids surface B 2009; 72: 303-311.
12. Panyam J, Zhou WZ, Probha S, Sahoo S, Labhasetwar V. Rapid endo-lysosomal escape of poly (D,Llactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB 2002; 16: 1217-1226.
13. Langer K, Balthasar S, Vogel V, Dinauer N, Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int. J. Pharm. 2003; 257: 169-180.
14. León-Rodrigueza L, Leiro-Vidalb J, lanco-Méndeza J, Luzardo-Álvarez A. Incorporation of PVMMA to PLGA MS enhances lectin grafting and their in vitro activity in macrophages. Int. J. Pharm. 2010; 402: 165-174.
15. Radomska-Soukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007; 59: 411-418.
16. Mishra PR., Al Shaal L, Müller R.H, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 2009; 371: 182-189.
17. Butsele KV, Sibreta P, Fustin CA, Gohyb JF, Passirani C, Benoitc JP. Synthesis and pH-dependent micellization of diblock copolymer mixtures. J. Colloid. Interf. Sci. 2009; 329: 235- 243.
18. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting' Nanomed- Nanotechnol. 2010; 6: 714- 729.
19. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanocapsulation I. methods for preparation of drug-loaded polymeric nanoparticles. Nanomed-Nanotechnol. 2006; 2: 8-21.
20. Ciani L, Ristori S, Bonechi C, Rossi C, Martini G. Effect of the preparation procedure on the structural properties of oligonucleotide/cationic liposome complexes (lipoplexes) studied byelectron spin resonance and Zeta potential. Biophys. Chem. 2007; 131: 80-87.
21. Patila S, Sandberg A, Heckert E, Self W, Sea S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials 2007; 28: 4600-4607.
22. Chen Ch, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 2010; 74: 474-482.
23. Bernfild M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulphate proteoglycans. Annu. Rev. Biochem. 1999; 68: 729-777.
24. Mislick K A, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A 1996; 93: 12349-12354.
25. Panyam P, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cell and tissue. Adv. Drug. Deliv. Rev. 2003; 55: 329-347.
26. Harting SM, Greene RR, Dikov MM, Prokop A. Davidson JM, Multifunctional nanoparticulate polyelectrolyte complexes. Pharm. Res. 2007; 24: 2353-2369.
27. Wilhelma C, Billoteya C, Rogerc JN, Bacria J, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003; 24: 1001- 1011.
28. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Control. Release 2010; 145: 182-195.
29. Limbach LK, Li Y, Grass RN, Brunner TJ, Hintermann MA, Muller M. Oxide nanoparticle uptake in human lung fibroblasts: effects of particle size, agglomeration, and diffusion at low concentrations. Environ. Sci. Technol. 2005; 39: 9370-9376.
30. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713-2722.
31. Nam HY. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. control. Release 2009; 135: 259- 267.
32. Cheng H, Zeng J, Jing Y, Zhang X, Zhuo R. Targeted gene delivery mediated by folate-polyethylenimineblock-poly(ethylene glycol) with receptor selectivity. Bioconjugate. Chem. 2009; 20: 481-487.
33. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliver. Rev. 2008; 60: 1037-1055.
34. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. drug deliver. Rev. 2001; 47: 65-81.
35. Park JS, Han TH, Lee KY, Han SS, Hwang JJ, Mon DH, Kim SY, Cho YW. N-acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: Endocytosis, exocytosis and drug release. J. Control. Release 2006; 115: 37-45.
36. Staples M, Daniel K, Cima MJ, Langer R. Application of Micro- and Nano-Electromechanical Devices to Drug Delivery. Pharm. Res. 2006; 23: 847-863.
37. Chang JH, Cho MA, Son HH, Lee CK, Yoon MS, Cho HH, Seo DS, Kim KJ. Characterization and formation of phospholipid nanoemulsion coatings on Mg-modified sericite surface. J. Ind. Eng. Chem, 2006;12: 635-638.
38. Robert BCampbell, Positively-charged liposomes for targeting tumor vasculature, Nano technology for cancer therapy, CRC Press, Taylor & Francis; 2007. 613p.
39. Hoeller S, Sperge, A, Valenta C. Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine on physicochemical behaviour and skin permeation. Int. J. Pharm. 2009; 370: 181-186.
40. Cazares-Delgadillo J, Naik A, Kalia YN, Quintanar--Guerrero D, Ganem-Quintanar A. Skin permeation enhancement by sucrose esters: a pH-dependent phenomenon. Int. J. Pharm. 2005; 297: 204-212.
41. Hoeller S, Sperger A, Valenta C. Lecithin based nanoemulsions: A comparative study of the influence of non-ionic surfactants and the cationic phytosphingosine onphysicochemical behaviour and skin permeation. Int. J. Pharm. 2009; 370: 181-186.
42. Coulmana SA, Anstey A, Gateleyb C, Morrisseyc A, McLoughlind C, Allendera C, Birchall JC. Microneedle mediated delivery of nanoparticles into human skin. Int. J. Pharm. 2009; 366: 190-200.
43. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002; 62: 6132-6140.
44. Yang R, Han X, Shia, X, Cheng G, Shim Ch, Cui F. Cationic formulation of paclitaxel-loaded poly D,Llactic-co-glycolic acid (PLGA) nanoparticles using an emulsion-solvent diffusion method. Asian J. Pharmaceut. Sci. 2009; 4: 89-95.
45. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release. 2003; 91: 103-113.
46. Mahoney BP, Raghunand N, Baggett B, Gillies RJ. Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 2003; 66: 1207-1218.
47. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. High resolution pHe imaging of rat glioma using pH-dependent relaxivity. Magn. Reson. Med. 2006; 55: 309-315.
48. Yang R, Shima WS, Cuic FD, Chengc G, Hanc X, Jin QR, Kima DD, Chunga S, Shima CK. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm. 2009; 371: 142-147.
49. Chen X, Wang X, Wang Y, Yang, L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X., Mao Y, Wei Y, Chen L. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J. Control. Release 2010; 145: 17-25.
50. Sethuraman VA, Han Bae Y. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J. Control. Release 2007; 118: 216-224.
51. Needham D, Ponce A. Nanoscale drug delivery vehicles for Solid tumors, Nanotechnology for cancer therapy, CRC Press, Taylor & Francis; 2002; p 677.
52. Dubernet BC, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliver. Re., 2002; 54: 631-651.
53. Cafaggi S, Russo E, Stefani R, Leardi R, Caviglioli G, Parodi B, Bignardi G, Detotero D, Viale M. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin- alginate complex. J. Control. Release 2007; 121: 110-123.
54. Yang R, Yong SG, Shim WS, Cui F, Cheng G, Kim IW, Kim DD, Chung SJ, Shim CK. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J. pharm Sci. 2009; 98: 970-984.
55. Chun ChJ, Lee SM, Kim S, Yang H, Song SC. Thermosensitive poly(organophosphazene)- paclitaxel conjugate gels for antitumor applications. Biomaterials 2009; 30: 2349-2360.
56. Gregoriadis G. Liposomes technology, Volume III CRC Press, Taylor & Francis; 2007. 156p.
57. Beduneau A, Saulnier P, Benoit JP. Active targeting of brain tumors using nanocarriers. Biomaterials 2007; 28: 4947-4967.
58. Park JH, Lee S, Kim J, Park K, Kim K, Kwon IC. Polymer nanomedicine for cancer therapy. Prog. Polym. Sci. 2008; 33: 113-137.
59. Kommareddy S, Shenoy DB, Amiji MM. Long-circulating polymeric nanoparticles for drug and gene delivery to tumors, Nano technology for cancer therapy, CRC Press, Taylor & Francis; 2007; p 231.
60. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles. Drug Discov. Today 2008; 13: 1099-1106.
61. Kaur IP, Bhandari R., Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control Release 2008; 127: 97-109.
62. Parikh T, Bommana MM, Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur. J. Pharm. Biopharm. 2010; 74: 442-450.
63. Chena H, Tanga I, Qina Y, Yina Y, Tanga J, Tanga W, Suna X, Zhanga Z, Liuc J, Hea Q. Lactoferrinmodified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 2010; 40: 94-102.
64. Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L. The blood- brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Bioph. Res. Co. 2010; 394: 871-876.
65. Wanga S, Jianga T, Maa M, Hua Y, Zhangb J. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting. Int. J. Pharmaceut. 2010; 386: 249-255.
66. Huang M, Khor E, Lim LY. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 2004; 21: 344-353.
67. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJA, Jiskoot W. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine 2007; 25: 144-153.
68. Khdair A, Chen D, Patil Y, Ma L, Dou P, Shekhar M,Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J. Control. Release 2010; 141: 137-144.
69. Lei T, Srinivasan S, Tang Y, Manchanda R, Nagesetty A, Fernandez-Fernandez A, McGoron AJ. Comparing cellular uptake and cytotoxicity of targeted drug carriers in 2 cancer cell lines with different drug resistance mechanisms. Nanomed-Nanotechnol. 2011; 7: 324-332.
70. Zhang Y, Tang L, Sun L, Bao J, Song C., Huang L, Liu K, Tian Y, Tian G, Li Z, Sun H, Mei L. A novel paclitaxel-loaded poly(e-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta. Biomater. 2010; 6: 2045-2052.